α-Blockers in Hypertension
Author:
- 1 January 1999
- journal article
- review article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 15 (2) , 95-103
Abstract
Hypertension is a heterogeneous disease and this is reflected in the marked variability in response to monotherapy. Co-administering antihypertensive therapies has several theoretical benefits, namely enhanced efficacy, improved tolerability, increased compliance and, in some cases, potentially beneficial changes in biochemical variables associated with increased cardiovascular risk, such as improvements in lipid profiles. α1-Blockers, such as doxazosin, have several favourable properties which should be advantageous when used with other agents. Their mechanism of action is complementary to that of each of the other four main groups of antihypertensive drugs and, in each case, enhanced efficacy has been observed when α1-blockade has been added to monotherapy with other drug classes. Synergistic effects have been seen when an α1-blocker is administered together with either a calcium channel blocker or angiotensin-converting enzyme inhibitor. While α1-blockers induce regression of left ventricular hypertrophy, the possibility of enhanced effects during multiple therapy has not been explored, α1-Blockers exert positive effects on lipids (limited data suggest that they are able to reverse the deleterious lipid effects of diuretics and β-blockers) and exert neutral or positive effects on glucose homeostasis. Further studies are needed to determine whether α1-blockers can alleviate the adverse effects of β-blockers or diuretics on glucose homeostasis, α1-Blockers, when given concomitantly with other antihypertensive drugs, are well tolerated, conferring advantages with respect to patient compliance. The current data favour the use of α1-blockers as an additional component of antihypertensive therapy, but further studies are needed to address the metabolic and end-organ effects of such treatment regimens.Keywords
This publication has 36 references indexed in Scilit:
- Maintaining long-term control of blood pressure: The role of improved complianceClinical Cardiology, 1995
- DoxazosinDrugs, 1995
- Low Dose Combination Antihypertensive Therapy Additional Efficacy Without Additional Adverse Effects?Drug Safety, 1995
- Antihypertensive and Metabolic Effects of Concomitant Administration of Terazosin and Methyclothiazide for the Treatment of Essential HypertensionThe Journal of Clinical Pharmacology, 1992
- The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by by β-blockersAmerican Heart Journal, 1991
- Management of multiple risk factors for coronary heart disease in patients with hypertensionAmerican Heart Journal, 1991
- A long-term study of doxazosin in the treatment of mild or moderate essential hypertension in general medical practiceAmerican Heart Journal, 1991
- A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapyAmerican Heart Journal, 1988
- Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapyAmerican Heart Journal, 1988
- Blood Lipid Levels and Antihypertensive TherapyDrugs, 1988